ATXS Stock Price, Astria Therapeutics, . Quote, Chart

Market Summary

USD9.55+0.12

Delayed

1.27%

ATXS Stock Price

View Fullscreen

ATXS RSI Chart

ATXS Valuation

Market Cap

524.4M

Price/Earnings (Trailing)

-6.42

Price/Free Cashflow

-7.06

ATXS Price/Earnings (Trailing)

ATXS Profitability

Return on Equity

-22.2%

Return on Assets

-21.55%

Free Cashflow Yield

-14.17%

ATXS Fundamentals

ATXS Earnings

Earnings (TTM)

-81.6M

Earnings Growth (Yr)

-78.12%

Earnings Growth (Qtr)

36.56%

Breaking Down ATXS Revenue

Last 7 days

-1.8%

Last 30 days

-9.5%

Last 90 days

-31.6%

Trailing 12 Months

-24.0%

How does ATXS drawdown profile look like?

ATXS Financial Health

Current Ratio

33.83

ATXS Investor Care

Shares Dilution (1Y)

95.94%

Diluted EPS (TTM)

-2.4

Tracking the Latest Insider Buys and Sells of Astria Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	morabito christopher	sold	-135,939	13.5939	-10,000	chief medical officer
Apr 01, 2024	morabito christopher	acquired	38,700	3.87	10,000	chief medical officer
Feb 01, 2024	perceptive advisors llc	bought	29,999,500	12.09	2,481,350	-
Jan 29, 2024	morabito christopher	sold	-102,552	11.147	-9,200	chief medical officer
Jan 29, 2024	morabito christopher	acquired	35,604	3.87	9,200	chief medical officer
Jan 26, 2024	morabito christopher	sold	-8,812	11.015	-800	chief medical officer
Jan 26, 2024	morabito christopher	acquired	3,096	3.87	800	chief medical officer
Dec 21, 2023	perceptive advisors llc	bought	4,588,000	6.2	740,000	-
Oct 16, 2023	perceptive advisors llc	bought	7,000,000	6.514	1,074,610	-
Dec 19, 2022	perceptive advisors llc	bought	10,000,000	11.01	908,265	-

Which funds bought or sold ATXS recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	Tidal Investments LLC	new	-	1,663,660	1,663,660	0.03%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-15.59	168,366	476,158	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-7.92	28,754	70,572	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	657	21,782,900	23,473,500	0.01%
May 15, 2024	DAFNA Capital Management LLC	reduced	-50.28	-305,926	3,142,460	0.72%
May 15, 2024	ADAGE CAPITAL PARTNERS GP, L.L.C.	new	-	22,535,400	22,535,400	0.04%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	1,203	2,879,720	3,005,490	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-40.4	24,115	285,596	-%
May 15, 2024	Royal Bank of Canada	reduced	-91.11	-80,000	16,000	-%
May 15, 2024	Voya Investment Management LLC	added	15.76	117,364	222,019	-%

Are Funds Buying or Selling ATXS?

Are funds buying ATXS calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ATXS

No. of Funds

Unveiling Astria Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Mar 07, 2024	blackrock inc.	4.5%	2,455,653	SC 13G/A
Feb 14, 2024	deep track capital, lp	0%	0	SC 13G/A
Feb 14, 2024	fairmount funds management llc	9.9%	3,633,965	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 13, 2024	vivo opportunity, llc	4.5%	2,482,727	SC 13G/A
Feb 13, 2024	vanguard group inc	5.66%	2,055,707	SC 13G
Feb 12, 2024	ra capital management, l.p.	8.1%	4,413,150	SC 13G
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 05, 2024	perceptive advisors llc	11.9%	6,485,420	SC 13D/A

Recent SEC filings of Astria Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
May 09, 2024	10-Q	Quarterly Report
Apr 22, 2024	ARS	ARS
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 09, 2024	3	Insider Trading
Apr 09, 2024	4	Insider Trading
Apr 09, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 25, 2024	8-K	Current Report

Peers (Alternatives to Astria Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	233.93%	75.07%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Astria Therapeutics, Inc. News

Latest updates

Astria Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	48.7%	379	255	194	207	218	231	120	105	115	128	135	141	149	47.00	57.00	57.00	59.00	42.00	44.00	49.00	54.00
Current Assets	49.2%	375	251	191	204	215	228	118	104	114	127	135	140	148	46.00	56.00	56.00	57.00	39.00	43.00	47.00	53.00
Cash Equivalents	-1.9%	172	176	120	134	202	21.00	46.00	30.00	47.00	87.00	132	140	147	25.00	53.00	52.00	13.00	10.00	18.00	10.00	12.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00
Liabilities	-4.1%	11.00	12.00	9.00	7.00	7.00	9.00	7.00	6.00	5.00	5.00	5.00	4.00	9.00	7.00	8.00	6.00	5.00	6.00	6.00	5.00	5.00
Current Liabilities	-4.1%	11.00	12.00	9.00	7.00	7.00	9.00	6.00	5.00	5.00	5.00	5.00	4.00	4.00	6.00	7.00	6.00	5.00	5.00	6.00	5.00	4.00
Shareholder's Equity	51.3%	368	243	184	200	211	221	113	99.00	110	122	130	137	330	41.00	49.00	0.00	54.00	36.00	38.00	254	253
Retained Earnings	-3.4%	-600	-580	-549	-531	-518	-507	-494	-482	-471	-455	-446	-438	-431	-260	-251	-241	-231	-223	-216	-210	-203
Additional Paid-In Capital	19.8%	873	728	638	636	635	633	511	486	484	482	480	475	330	302	301	292	285	259	255	254	253
Shares Outstanding	33.8%	55.00	41.00	28.00	28.00	28.00	28.00	14.00	13.00	13.00	13.00	8.00	5.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	280	-	-	-	26.00	-	-	-	130	-	-	-	101	-	-	-	73.00	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	36.9%	-19,094	-30,238	-14,258	-10,696	-13,253	-10,664	-10,249	-10,061	-12,559	-6,286	-7,749	-7,400	-8,716	-8,061	-9,969	-7,466	-6,989	-7,770	-6,474	-5,738	-6,587
Share Based Compensation	33.1%	2,754	2,069	1,694	1,331	1,220	1,073	1,155	1,117	1,209	972	1,010	1,014	366	305	375	-	-	285	378	441	408
Cashflow From Investing	-6161.5%	-126,231	-2,016	-4.00	-57,920	194,992	-135,180	1,950	-6,800	-27,099	-39,000	-	-	26,445	-20,010	2,000	39,742	-15,432	-3,504	13,651	3,509	-17,738
Cashflow From Financing	61.2%	141,807	87,978	110	273	37.00	120,397	-	-	-	17.00	6.00	-	104,261	31.00	8,940	6,265	25,624	3,772	973	192	20,683

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ATXS Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 15,726	$ 8,033
General and administrative	8,424	5,460
Total operating expenses	24,150	13,493
Loss from operations	(24,150)	(13,493)
Other income (expense):
Interest and investment income	4,241	2,321
Other expense, net	(19)	(16)
Total other income, net	4,222	2,305
Net loss	$ (19,928)	$ (11,188)
Net loss per share attributable to common shareholders - basic	$ (0.38)	$ (0.40)
Net loss per share attributable to common shareholders - diluted	$ (0.38)	$ (0.40)
Weighted-average common shares outstanding used in net loss per share - basic	52,294,765	27,944,458
Weighted-average common shares outstanding used in net loss per share - diluted	52,294,765	27,944,458

ATXS Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 172,012	$ 175,530
Short-term investments	197,895	71,000
Prepaid expenses and other current assets	4,614	4,412
Total current assets	374,521	250,942
Right-of-use asset	210	363
Other assets	4,076	3,361
Total assets	378,807	254,666
Current liabilities:
Accounts payable	862	1,513
Accrued expenses	10,042	9,708
Current portion of operating lease liabilities	168	329
Total current liabilities	11,072	11,550
Total liabilities	11,072	11,550
Commitments (Note 6)
Stockholders' equity:
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 54,903,061 and 41,034,797 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	55	41
Additional paid-in capital	872,832	728,285
Accumulated other comprehensive loss	(14)
Accumulated deficit	(600,462)	(580,534)
Total stockholders' equity	367,735	243,116
Total liabilities and stockholders' equity	378,807	254,666
Preferred stock
Stockholders' equity:
Preferred stock
Series X redeemable convertible preferred stock
Stockholders' equity:
Preferred stock	$ 95,324	$ 95,324

About Astria Therapeutics, Inc.

Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.

CEO	Ms. Jill C. Milne Ph.D.
WEBSITE	astriatx.com
INDUSTRY	Biotechnology
EMPLOYEES	45

Astria Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Astria Therapeutics, Inc.? What does ATXS stand for in stocks?

ATXS is the stock ticker symbol of Astria Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Astria Therapeutics, Inc. (ATXS)?

As of Fri May 17 2024, market cap of Astria Therapeutics, Inc. is 524.42 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers.

What is the fair value of ATXS stock?

You can check ATXS's fair value in chart for subscribers. The fair value of Astria Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Astria Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ATXS so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Astria Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether ATXS is over valued or under valued. Whether Astria Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Astria Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXS.